论文部分内容阅读
盐酸厄洛替尼是一种口服高效表皮生长因子受体酪氨酸激酶(EGFR)选择性抑制药,通过影响细胞内磷酸化过程来抑制信号通路的传导,进而抑制肿瘤细胞的扩散及增殖来达到抗肿瘤的目。大型临床研究证实,厄洛替尼靶向治疗非小细胞肺癌(NSCLC)晚期,能显著延长患者的生存期。而对于老年及身体状态评价差的患者,厄洛替尼单药不失为一线治疗的新选择。本文讨论了1例NSCLC晚期患者单药使用盐酸厄洛替尼靶向治疗过程中出现严重药物疹及其他不良反应的药学监护。
Erlotinib Hydrochloride is a selective and orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR), which inhibits the signal transduction through the influence of intracellular phosphorylation and thus inhibits the proliferation and proliferation of tumor cells To the anti-tumor head. Large-scale clinical studies have confirmed that erlotinib targeted therapy for advanced non-small cell lung cancer (NSCLC) can significantly prolong the survival of patients. For patients with poor evaluation of the elderly and physical condition, erlotinib monotherapy may be a new first-line treatment of choice. This article discusses the pharmacogenetics of one case of severe drug eruption and other adverse reactions during the targeted therapy of erlotinib hydrochloride in one patient with advanced NSCLC.